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Neonatal portal vein thrombosis (PVT) is a rare disease, with
an incidence of 1 in 100,000 live births1 and 36 per 1,000
infants hospitalized in neonatal intensive care units (NICUs).2
The coagulation system of infants develops with age, as
documented by considerable differences in the concentration
of clotting proteins compared with adults; therefore, the
thrombotic risk is signiﬁcantly reduced in children.3
The etiology of portal vein occlusion in infants is multifacto-
rial. Primitive (malformations, thrombophilic genetic defects,
prematurity, low birth weight) and/or secondary (trauma, hyp-
oxia) risk factors play a key role in the pathogenesis of the
disease, which commonly occurs secondary to the placement of
an umbilical vein catheter (UVC), with or without infection.4
Here, we report on a preterm newbornwith PVT associated
with mutation of the methylenetetrahydrofolate reductase
(MTHFR) and plasminogen activator inhibitor-1 (PAI-1) genes
and sepsis by Candida parapsilosis.
Clinical Report
A male neonate was born at 32 þ 5 gestational weeks in
another NICU of town by cesarean delivery because of breech
presentation. Intrauterine growth restriction (IUGR) occurred
during pregnancy, likely due to extensively infarctedmultiple
hemorrhagic areas documented by histological examination
of the placenta. Birthweight was 1,110 g (2nd centile), length
Keywords
► portal thrombosis
► umbilical catheter
► fungal infection
► anticoagulation
therapy
► thrombophilia
► gene polymorphism
Abstract Objective This report discusses the role of both congenital and acquired risk factors in
the pathogenesis of portal vein thrombosis (PVT).
Study Design Wedescribe the clinical management and treatment of PVT in a preterm
newborn with a homozygous mutation of the methylenetetrahydrofolate reductase
(MTHFR) and plasminogen activator inhibitor-1 (PAI-1) genes and sepsis by Candida
parapsilosis.
Results Although literature data suggest a minor role of genetic factors in thrombo-
philia in the case of only one mutation, we hypothesize that combined thrombophilic
genetic defects may have a cumulative effect and signiﬁcantly increase the thrombotic
risk.
Conclusion It could be appropriate to include more detailed analyses of procoagulant
and ﬁbrinolytic factors in the diagnostic workup of neonatal thrombosis, also through
the investigation of genetic polymorphisms. The anticoagulant therapy and the removal
of concurrent risk factors remain basic steps for the adequate management and
prevention of complications.
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37.5 cm (2nd centile), and head circumference 27.2 cm (2nd
centile). Apgar scores measured at 1, 5 and 8 minutes were
reported as 1, 5 and 8, respectively. The infant was immedi-
ately intubated and ventilated. A UVC was inserted and total
parenteral nutrition (TPN)was started, integrated byminimal
enteral feeding (MEF) with mother’s milk administered
through the nasogastric tube. On the sixth day of life, because
of enteral feeding intolerance, MEF was suspended, the
umbilical catheter was removed, and TPN was continued
through a peripherally inserted central catheter (PICC). On
the 11th day of life, enteral feeding with mother’s milk and
the formula was started again. After a week enteral nutrition
was suspended again because of gastric residuals, abdominal
distension, rigidity, and pain; abdominal X-rays revealed
distension of ileum and not evident colon; laboratory tests
revealed infection markers as thrombocytopenia (platelet
count 34  103/µΛ), C-reactive protein 4.8 mg/dL (normal
values < 1 mg/dL), high levels of aminotransferases (aspar-
tate aminotransferase: 732 U/L, alanine aminotransferase:
234 U/L), and signs of cholestasis (total bilirubin: 18.4 mg/dL,
direct bilirubin: 16.46 mg/dL, gamma-glutamyl transferase:
137 U/L, alkaline phosphatase: 578 U/L). Blood culture was
included in the diagnostic workup.
At 20 days of life, with the suspicion of intestinal occlusion,
the baby was transferred to our NICU which is linked to a
Pediatric Surgery Unit. On admission, he presented with
jaundice, protruding abdomen, hepatosplenomegaly, bilat-
eral hydrocele, hypotonia, and poor reactivity. Abdominal
X-rays conﬁrmed ileal obstruction and abdominal ultraso-
nography (US) showed diffused corpuscular effusion in the
peritoneum, ileal loop distension with wall thickening.
Patient parents received adequate communication and gave
informed consent to the required surgical and medical treat-
ments and the appropriate genetic investigations. Urgent
surgical intervention of transverse laparotomy demonstrated
the presence of a perihepatic abscess originated from a septic
thrombus of the umbilical vein, drainage of the collection and
removal of umbilical vessels were performed (►Fig. 1 A, B).
The dayafter admission, result of the blood culture performed
before the transfer revealed Candida parapsilosis, therefore
PICC was replaced and treatment with micafungin was
started pending the results of the antimicogram, which
subsequently showed susceptibility to the above-mentioned
echinocandin (minimal inhibitory concentration [MIC]
value: 2 µg/mL), ﬂuconazole and amphotericin-B (MIC value:
0.5 µg/mL for both). Postoperative abdominal US showed
hepatosplenomegaly and a clot in the left branch of the
hepatic portal vein (►Fig. 2) with subsequent extension to
the right branch in the following week. Thrombophilic
genetic analyses revealed a homozygous mutation in the
MTHFR gene (C677T) and the homozygous 4G/4G polymor-
phism in the PAI-1 gene. Once excluded contraindications
such as bleeding, intracranial hemorrhage, or cerebral infarct,
treatment with subcutaneous enoxaparin was initiated at
1 month of life, with close instrumental monitoring of the
thrombus and control of plasmatic levels of coagulation
factors. The anticoagulant therapy was discontinued after
1 month of treatment because of reduction in the size of the
clot and its regression to the left branch of the portal vein. No
side effects have been reported.
During the ﬁrst 3 weeks of hospitalization, general
conditions of the patient were poor with persistently elevated
inﬂammatory markers and worsening cholestasis. Repeated
microbiological samples (blood cultures, septifast molecular
test, and PICC culture) in the course of echinocandin treat-
ment were still positive for C. parapsilosis and showed
progressive decrease of susceptibility to micafungin until
resistance. Therefore, ﬂuconazole therapy (supported by
the lowest MIC value, 0.06 µg/mL) was added for a week.
Finally, because of evidence of micafungin resistance and no
clinical/biochemical improvement nor negativization of
blood cultures, antifungal treatment was shifted to liposomal
amphotericin-B (MIC value 0.5 µg/mL) administered for
3 weeks, which allowed gradual clinical and biochemical
Fig. 1 (A) It is clearly visible the septic thrombus in the umbilical vein (upper arrow), and a small abscess in the hepatic inlet of the vessel (lower
arrow); (B) extension of the perihepatic abscess to the falciform ligament and to the peritoneum.
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improvement, reduction of the signs of cholestasis and of
hypertransaminasemia, and negativization of molecular test
and blood culture (after 10 and 20 days of treatment,
respectively).
The infant was discharged in the 11thweekof life in a good
general health state and follow-up has been performed at
Pediatric Surgery outpatient clinic in our department. At
present, the patient is 18 months old, he develops normally,
and liver US follow-up shows a partial regression of the
thrombotic lesion with the improvement of portal vascular
circulation.
Discussion
Neonatal PVT is a rare disease, with variable incidence from
0.7 to 5.1/100,000 live births.5 Preterm newborns carry a
signiﬁcant risk for thrombosis, about half cases occurring in
these patients, and continuous advances in medical and
surgical management, which improve survival of preterm
infants, may increase the incidence of thrombotic events.5
PVT is due both to congenital (malformations, thrombo-
philia, gestational age, birth weight, etc.) and secondary (infec-
tion, trauma, vessel catheterization, etc.) risk factors, with
central venous line placement being the most important one
in the neonatal period. In the case of improper insertion of the
catheter into the portal vein, there may be thrombosis of
hepatic vessels and other complications such as necrotizing
enterocolitis, intestinal perforation, and portal hypertension.6
Perihepatic and liver abscesses are even rarer complications of
a systemic infection in neonatal age. These uncommon events
can happen, however,more easily in infantswith sepsis and/or
malposition of the umbilical catheter. Therefore, a diagnosis of
hepatic/perihepatic abscess should be considered in any new-
born with increasing markers of infection, thrombocytopenia,
and abdominal manifestations (feeding intolerance, protrud-
ing abdomen, hepatosplenomegaly). All these signs were
present in our patient, although we cannot establish with
reasonable certainty if the thrombus occurred before or after
the fungal infection, since both are plausible causes of the
clinical symptoms.
Two studies reported that low birth weight and early
gestational age (especially with IUGR) could predispose to
thrombosis, as occurred in our patient.7Moreover, there have
been reports of thrombophilia associated with PVT in new-
borns.4 However, the contribution of genetic or acquired
thrombophilia in the causation of thrombosis in preterm
infants is unknown. It is likely that congenital and acquired
risk factors are present in the same patient. A condition of
inherited thrombophilia should be suspected and screened in
the case of recurrent thromboembolism, early onset in young
age, unusual localization (mesenteric veins, portal vein, cere-
bral veins), and familiarity. There are no global tests, to date,
that allowan easy diagnosis of thrombophilia, but there is the
need to perform several analyses according to a standardized
protocol.8 Among candidate genes for thrombotic risk, there
are mainly those encoding for procoagulant factors including
factor V, factor XIII, human platelet alloantigens, and
β-ﬁbrinogen. Some polymorphisms of the ﬁbrinolytic system
(PAI-1), homocysteine cycle (MTHFR), renin-angiotensin
system (ACE), and of lipid metabolism (APO-B and APO-E)
are positively or negatively associated with thrombosis. We
studied all these genes in our patient and we found two
mutations/polymorphisms. TheMTHFR gene carries a homo-
zygous C677T mutation, which determines a substitution of
alanine with valine in the ﬁnal protein with consequent
decreased enzymatic activity, very high levels of homocyste-
ine and severe thrombotic events. In addition, we found a
homozygous one base pair polymorphism 4G/4G in the
promoter region of PAI-1 gene, which consists in a deletion
of a guanine at position 675 compared with the wild type 5G.
Fig. 2 Hepatic ultrasound shows the clot in the left branch of the hepatic portal vein.
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The 4G allele could just bind enhancers of transcription, while
5G interacts with enhancers and suppressors; this results in a
lower level of transcription in the presence of the 5G allele.
Several studies demonstrated that 4G/5G individuals have
higher PAI-1 plasmatic levels with consequent inhibition of
ﬁbrinolysis and stored ﬁbrin; homozygotes 4G/4G have PAI-1
plasmatic levels 25% higher than 5G/5G subjects, with
increased thrombotic risk.8 Thus, although some reports
did not ﬁnd an association between thrombophilia and
thrombosis and MTHFR did not appear to add signiﬁcant
risk for neonatal PVT,4 preterm infants with prothrombotic
mutations are more likely to develop thrombotic events in
case of concurrent clinical triggers such as sepsis or indwell-
ing catheters. Moreover, the unique genetic pattern of our
patient with a double homozygous mutation/polymorphism
of the MTHFR and PAI-1 genes, not described to date, could
have signiﬁcantly increased the thrombotic risk. This hypoth-
esis is also strengthened by the placental histological ﬁndings
of fetal thrombotic vasculopathy (FTV), that was likely
responsible for the IUGR. FTV together with a history of
recurrent miscarriages were highly suggestive for inherited
thrombophilia. Genetic analyses of parental thrombophilic
proﬁle revealed they were both heterozygous for the same
MTHFR mutation of the propositus, in addition, the father
resulted homozygous and themother heterozygous for the 4G
polymorphism of PAI-1. These results were compatible with
the homozygous condition of the proband for both the genes.
The long permanence (6 days) of the UVC may have
contributed increasing the chance of complications together
with the other risk factors. According to literature data,4,6,7,9
we agree on the importance of limiting the length of stay of
central vein catheters in neonates (72–96 hours for UVC).
C. parapsilosis sepsis certainly inﬂuenced the clinical
course, acting as a concurrent trigger (or even an additional
risk factor) for the thrombus, and was ﬁnally eradicated by
liposomal amphotericin-B treatment. Although the beneﬁt of
azole prophylaxis in reducing the incidence of invasive
candidiasis in small infants is well documented and mica-
fungin has a speciﬁc authorization (license) for neonatal
treatment,10 concerns have been raised over both ﬂuconazole
and micafungin efﬁcacy in vivo. The lowest MIC values were
registered for ﬂuconazole, but we did not observed any
clinical beneﬁt likely representing an inability to act in a
speciﬁc fungal sanctuarium (such as the thrombus or the
indwelling catheter bioﬁlm) rather than a sign of emerging
azole resistance. In the past decade, echinocandins are prov-
ing to be a very useful addition to the antifungal armamen-
tarium and have shown activity against the bioﬁlms
associated with various Candida species, including C. para-
psilosis.11 Nevertheless, micafungin treatment was not suc-
cessful in our patient and the progressive increase of MIC
values up to resistance may reﬂect, in our experience, a lower
efﬁcacy against C. parapsilosis (as previously documented by
other authors12,13) rather than a mechanical barrier by the
thrombus which obstacles the antifungal activity on the cell
wall, causing then second the establishment of resistance.
Furthermore, although worldwide surveillance of C. para-
psilosis indicated very low rates of resistance and low inci-
dence of nonwild type, it cannot be excluded thatmutation or
acquisition of genes not known to date could change its
resistance proﬁle and then the epidemiology of the infection.
Therefore, ongoing monitoring appears to be necessary to
determine if strains of C. parapsilosis and other Candida spp.
are developing resistance to ﬂuconazole and/or to echino-
candins.12 In this perspective whole fungal genome sequenc-
ing could be useful, to detect new possible mutations able to
induce resistance and, as a result, to promptly address the
most appropriate antifungal treatment.
Low-molecular-weight heparin or enoxaparin is the drug
of ﬁrst choice for anticoagulant therapy in the neonatal
period, because of its more stable pharmacokinetics, ease
of administration and less frequent monitoring.5 The optimal
duration of anticoagulant therapy in newborns is not yet well
deﬁned; however, it is generally recommended a short
treatment period (from 10 days to 3 months) with regular
monitoring of the thrombus.14
Enoxaparin treatment for amonth proved to be effective in
our patient together with appropriate antifungal treatment,
avoiding the extension of the thrombus and allowing its
partial resolution at 1 year follow-up. If the PVT does not
resolve spontaneously and/or it is not treated, the patient
may develop complications (cavernoma, portal hypertension,
liver lobe atrophy).4
Although literature data suggest a minor role of genetic
factors in thrombophilia in the case of onlyonemutation,4 the
coexistence of two homozygous mutations/polymorphisms
in our patient seems to have signiﬁcantly increased the
thrombotic risk. Therefore, it seems useful to include in the
diagnostic workup of neonatal thrombosis not only the
investigation of procoagulant factors, but also the study of
the ﬁbrinolytic system. However, the removal/resolution of
eventual additional concurrent risk factors (UVC, fungal
infection) and the anticoagulant therapy are necessary steps
to address a favorable clinical course and prevent further
complications.
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